Phase III trial results for three anti-obesity therapies suggest that they meet at least some of the efficacy benchmarks for regulatory approval, although questions remain about the value of the benefits offered.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Jones, D. Novel pharmacotherapies for obesity poised to enter market. Nat Rev Drug Discov 8, 833–834 (2009). https://doi.org/10.1038/nrd3044
Issue Date:
DOI: https://doi.org/10.1038/nrd3044
This article is cited by
-
Behavioral and pharmacologic therapies for obesity
Nature Reviews Endocrinology (2010)
-
Upcoming market catalysts in Q3 2010
Nature Reviews Drug Discovery (2010)